Life sciences company Avacta Therapeutics (AIM:AVCT) on Thursday reported new preclinical data showing that its investigational cancer drug AVA6207 overcame resistance to topoisomerase I inhibitors (TOP1i) in laboratory studies and animal models.
The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on 19 November 2026.
AVA6207 uses Avacta's pre|CISION technology to deliver two therapeutic payloads, exatecan and the ATR inhibitor berzosertib, directly to tumours through a single tumour-specific cleavage event. The combination is designed to prevent cancer cells from repairing DNA damage, potentially overcoming treatment resistance.
Preclinical studies demonstrated activity in tumours associated with SLFN11 loss and ATM deficiency, two mechanisms linked to increased dependence on ATR signalling. ATM-deficient cells showed approximately tenfold greater sensitivity to AVA6207 than ATM-positive cells, while the candidate reversed TOP1i resistance in SLFN11-deficient cells.
In patient-derived xenograft models, AVA6207 achieved complete responses in all animals with ovarian tumours and four of five animals with non-small cell lung cancer (NSCLC). The candidate also demonstrated superior activity to marketed antibody-drug conjugate Enhertu in a gastric cancer model.
Avacta is assessing biomarker-defined patient populations across colorectal, NSCLC, ovarian and oesophageal squamous cell cancers for potential clinical development. The company said payload selection has been completed and AVA6207 is expected to enter IND-enabling studies in the fourth quarter of 2026.
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177